Coagulation Disorders: DIC, TTP-HUS, and Anticoagulant Management

Thrombotic microangiopathies (TMAs) represent a spectrum of disorders characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and small vessel thrombosis [1]. These conditions share common pathophysiologic mechanisms but require distinct diagnostic and therapeutic approaches.

Disseminated Intravascular Coagulation (DIC) results from widespread activation of the coagulation cascade, leading to simultaneous thrombosis and bleeding. The pathogenesis involves:

• Tissue factor release triggering extrinsic coagulation pathway
• Consumption of coagulation factors and platelets
• Activation of fibrinolysis resulting in elevated D-dimer
• Microvascular thrombosis causing end-organ dysfunction

Thrombotic Thrombocytopenic Purpura (TTP) is caused by severe deficiency (<10%) of ADAMTS13 metalloprotease activity [1,3]. This deficiency can be:

• Acquired: Due to autoantibodies against ADAMTS13 (>95% of cases)
• Congenital: Due to mutations in the ADAMTS13 gene

The absence of ADAMTS13 leads to accumulation of ultra-large von Willebrand factor multimers, causing platelet aggregation and microvascular thrombosis.

Hemolytic Uremic Syndrome (HUS) traditionally associated with Shiga toxin-producing E. coli, but complement-mediated HUS (CM-HUS) represents a distinct entity caused by dysregulation of the alternative complement pathway.

[KEY_CONCEPT] The classic pentad of TTP (thrombocytopenia, MAHA, neurologic symptoms, fever, renal dysfunction) is present in <10% of cases at presentation [3].

Clinical manifestations vary significantly among TMAs, requiring systematic evaluation to differentiate these conditions [1].

DIC Clinical Features:

• Bleeding manifestations: Petechiae, ecchymoses, mucosal bleeding
• Thrombotic complications: DVT, PE, digital ischemia
• End-organ dysfunction: Acute kidney injury, hepatic dysfunction
• Associated conditions: Sepsis, malignancy, obstetric complications

TTP Clinical Features:

• Neurologic symptoms (present in 90%): Headache, confusion, focal deficits, seizures
• Thrombocytopenia with minimal bleeding (platelets typically <30,000/μL)
• MAHA with schistocytes on peripheral smear
• Fever (present in 60-70% of cases)
• Renal involvement (less prominent than in HUS)

[HIGH_YIELD] TTP represents a hematologic emergency with mortality approaching 90% if untreated, but <10% with prompt plasma exchange therapy [3].

Diagnostic Algorithm for TMA:

Patient with thrombocytopenia + MAHA + schistocytes ↓ Check: PT/INR, aPTT, fibrinogen, D-dimer ↓ Elevated PT/aPTT, low fibrinogen, high D-dimer? ↓ Yes ↓ No DIC Check ADAMTS13 activity ↓ <10% activity? ↓ Yes ↓ No TTP Consider HUS/other TMA ↓ Start plasma exchange IMMEDIATELY

[CLINICAL_PEARL] Do not wait for ADAMTS13 results to initiate plasma exchange if TTP is suspected clinically - delay increases mortality risk significantly.

Essential Laboratory Evaluation:

• Complete blood count with peripheral smear
• Comprehensive metabolic panel
• LDH, haptoglobin, indirect bilirubin
• ADAMTS13 activity and inhibitor levels
• PT/INR, aPTT, fibrinogen, D-dimer
• Blood cultures and infectious workup

Immediate Management of TTP requires urgent plasma exchange therapy, which remains the cornerstone of treatment [1,3].

First-line Therapy:

• Plasma exchange (PEX): 1.0-1.5 plasma volumes daily until platelet count >150,000/μL for 2 consecutive days
• Corticosteroids: Methylprednisolone 1-2 mg/kg/day or equivalent
• Caplacizumab: Anti-VWF nanobody, 11mg IV loading dose followed by 11mg subcutaneous daily

[HIGH_YIELD] Caplacizumab significantly reduces time to platelet normalization and reduces TTP-related death, thrombotic events, and major bleeding compared to plasma exchange alone.

Plasma Exchange Protocol:

1. Vascular access: Large-bore central venous catheter
2. Replacement fluid: Fresh frozen plasma (FFP) preferred over albumin
3. Monitoring: Daily CBC, metabolic panel, LDH
4. Discontinuation criteria:
   • Platelet count >150,000/μL × 2 days
   • LDH normalization
   • Clinical improvement

Refractory TTP Management:

• Increase PEX frequency to twice daily
• Rituximab: 375 mg/m² weekly × 4 doses for acquired TTP
• Immunosuppression: Cyclosporine, mycophenolate mofetil
• Splenectomy: Reserved for truly refractory cases

[KEY_CONCEPT] Relapse prevention in acquired TTP includes rituximab administration during acute episode, which reduces relapse rates from 57% to 10% at 6 months [3].

Monitoring During Treatment:

• Daily platelet count and hemoglobin
• LDH levels as marker of hemolysis
• Neurologic status assessment
• Renal function monitoring
• ADAMTS13 activity (goal >10% for remission)

Supportive Care Measures:

• Avoid platelet transfusions (may worsen thrombosis)
• Red blood cell transfusion for severe anemia
• Folic acid supplementation
• DVT prophylaxis with sequential compression devices
• Neurologic monitoring with appropriate imaging

DIC management focuses primarily on treating the underlying disorder while providing supportive coagulation management [2].

Diagnostic Criteria for DIC:

Score ≥5 = Compatible with overt DIC

Treatment Approach:

1. Treat Underlying Condition

• Antibiotics for sepsis
• Chemotherapy for malignancy
• Delivery in obstetric complications
• Supportive care for trauma

2. Coagulation Support

• Fresh frozen plasma: 10-15 mL/kg for bleeding with prolonged PT/aPTT
• Platelet transfusion: Goal >50,000/μL if bleeding, >20,000/μL if stable
• Cryoprecipitate: If fibrinogen <100 mg/dL (goal >150 mg/dL)
• Packed red blood cells: Maintain Hgb >7-8 g/dL

[CLINICAL_PEARL] Prophylactic factor replacement is not recommended in non-bleeding DIC patients as it may fuel the coagulation process.

3. Anticoagulation Considerations

• Heparin therapy: Consider in thrombosis-predominant DIC
• Low molecular weight heparin preferred
• Contraindicated with active bleeding
• Monitor anti-Xa levels rather than aPTT

4. Antifibrinolytic Therapy

• Tranexamic acid: Only if hyperfibrinolysis suspected
• Use with extreme caution due to thrombosis risk
• Generally contraindicated in DIC

Anticoagulation in patients with hematologic malignancies and coagulation disorders requires careful risk-benefit assessment due to bleeding and thrombotic risks [5].

Thrombosis Risk Factors in Hematology Patients:

• Malignancy-related: Hypercoagulable state, tumor burden
• Treatment-related: Central venous catheters, chemotherapy, steroids
• Patient-related: Immobilization, prior VTE, inherited thrombophilia

Anticoagulant Selection Algorithm:

Hematology patient with VTE indication ↓ Active bleeding or high bleeding risk? ↓ Yes ↓ No Defer anticoagulation Platelet count assessment Consider IVC filter ↓ >50,000/μL? <50,000/μL? ↓ ↓ Full anticoagulation Reduced dose or LMWH preferred hold until >50K

Anticoagulation Guidelines by Platelet Count:

[HIGH_YIELD] Low molecular weight heparin (LMWH) is preferred over warfarin in cancer patients due to superior efficacy and reduced bleeding risk.

Specific Considerations:

1. Cancer-Associated Thrombosis

• First-line: LMWH (enoxaparin, dalteparin) for initial 6 months
• Alternative: Rivaroxaban or edoxaban if no drug interactions
• Duration: Extended therapy often required

2. Immune Thrombocytopenia (ITP)

• Anticoagulation generally avoided until platelet count >50,000/μL
• Consider platelet-raising therapy (steroids, IVIG, TPO agonists) first
• If urgent anticoagulation needed, use shortest-acting agent with reversal available [4,6]

3. Post-Stem Cell Transplant

• High bleeding risk due to thrombocytopenia and mucositis
• Prophylactic dosing only when platelets >20,000/μL
• Monitor for hepatic veno-occlusive disease

[CLINICAL_PEARL] In thrombocytopenic patients requiring anticoagulation, platelet transfusion targets should be higher (>50,000/μL) and more frequent monitoring is essential.

Long-term complications of TMAs and anticoagulation in hematologic disorders require ongoing surveillance and management [1,2].

TTP Complications and Follow-up:

Acute Complications:

• Neurologic sequelae: Cognitive impairment, seizure disorders (10-15% of survivors)
• Cardiac involvement: Myocardial infarction, heart failure
• Renal dysfunction: Usually reversible, chronic kidney disease rare
• Plasma exchange complications: Line infections, citrate toxicity, allergic reactions

Long-term Management:

• ADAMTS13 monitoring: Every 3-6 months during remission
• Relapse surveillance: 30-50% risk within 10 years for acquired TTP
• Cardiovascular risk assessment: Increased long-term MI and stroke risk
• Pregnancy counseling: Plasma exchange safe, but increased relapse risk

[KEY_CONCEPT] TTP relapse typically occurs within first 30 days (early) or after 30 days (late). Early relapses may represent inadequate initial therapy.

DIC Complications:

• Bleeding complications: GI bleeding, intracranial hemorrhage, surgical bleeding
• Thrombotic complications: Digital ischemia, PE, stroke
• Organ dysfunction: Acute kidney injury, hepatic failure, ARDS
• Transfusion-related: Volume overload, transfusion reactions, alloimmunization

Anticoagulant Complications in Hematology:

Monitoring Parameters:

• Weekly CBC during acute management
• Coagulation studies every 2-3 days initially
• Anti-Xa levels for LMWH (goal 0.6-1.0 IU/mL)
• Clinical assessment for bleeding or thrombotic symptoms

Prevention Strategies:

• TTP: Rituximab prophylaxis in high-risk patients
• DIC: Early recognition and treatment of underlying conditions
• VTE: Appropriate thromboprophylaxis in hospitalized patients
• Bleeding: Minimize invasive procedures, optimize platelet counts

[CLINICAL_PEARL] Patients with history of TTP should avoid triggers including certain medications (quinine, ticlopidine) and maintain awareness of early symptoms for prompt treatment of relapses.